# Galderma (GALD): Agrees $1.5bn cash deal for ZO Skin Health, about 4.5 times its yearly sales

> Galderma, the Swiss skin-health group behind Cetaphil, said on 14 October 2026 that it will buy ZO Skin Health, a US brand of skincare sold through…

- URL: https://centiview.com/post/galderma-gald-agrees-1-5bn-cash-deal-for-zo-skin-health-about-4-5-times-its-yearly-sales
- Published: 2026-10-19T02:30:00.000Z
- Sectors: Healthcare
- Region: Europe
- Ticker: GALD
- Sentiment (opinion, not a recommendation): neutral
- Publisher: Centiview (Persie Ltd, London)
- General information only, not financial advice

Galderma, the Swiss skin-health group behind Cetaphil, said on 14 October 2026 that it will buy ZO Skin Health, a US brand of skincare sold through doctors and medical spas, for $1.5bn in cash. ZO had sales of about $330m in the 12 months to June 2026, so the price is roughly 4.5 times its yearly sales. Galderma expects the deal to trim its profit margin slightly in 2027.

## What happened

On Wednesday 14 October 2026 Galderma (SIX: GALD) announced a signed agreement to acquire 100% of ZO Skin Health from its shareholders, which include funds managed by Blackstone Tactical Opportunities and the family of the founder, dermatologist Dr Zein Obagi. The price is an enterprise value of $1.5bn, meaning the value of the business including its debt, paid entirely in cash and subject to customary adjustments. Galderma will pay from existing cash and bank financing.

ZO is based in Irvine, California. It makes more than 40 products in the United States, built around daily routines using retinol, a vitamin A ingredient, and acids. It sells through more than 16,500 doctor, medical spa and online accounts in over 40 countries. Galderma says the products fit alongside Alastin, its skincare range used before and after cosmetic procedures, and the group's wider Dermatological Skincare business, which also includes Cetaphil.

## The numbers, explained

Start with the price. Enterprise value of $1.5bn divided by ZO's roughly $330m of net sales (sales after discounts and returns) is 4.5 times (1,500 divided by 330 is 4.55). That is a sales multiple, a way to compare price with size; it says nothing about profit, because neither Galderma nor ZO disclosed ZO's profit. Galderma says it will increase spending on selling and marketing in the first year after closing, expects growth to resume in the second year, and expects the deal to be slightly dilutive to Group Core EBITDA margin in 2027. Core EBITDA is the company's own measure of operating profit before depreciation and other adjustments. From 2028 the margin should be broadly in line with the group average, and Core EPS, its adjusted profit per share, should be neutral in the first full year.

Now the buyer. In the first half of 2026 Galderma reported net sales of $3,134m against $2,448m a year earlier, up 28.0% as reported (3,134 divided by 2,448 is 1.280) and 24.6% at constant currency, which strips out exchange-rate moves. Core EBITDA was $802m against $555m, a margin of 25.6% (802 divided by 3,134), against 22.7%. Core EPS was $2.34 against $1.39. Net debt, borrowings minus cash, was $1,786m, or 1.2 times Core EBITDA by the company's measure. Our simple illustration: adding $1,500m of cash outlay would lift net debt to about $3,286m before any ZO earnings, roughly twice a full-year EBITDA of $1,604m (first-half $802m doubled, ignoring seasonality). That is our arithmetic, not a company figure; Galderma says the deal fits a solid investment-grade credit rating.

Size matters too. Galderma's Dermatological Skincare division had first-half sales of $848m, up 16.4% at constant currency from $719m. Doubling that gives about $1,696m for a full year, so ZO's $330m would equal roughly a fifth of it (330 divided by 1,696 is 19.5%). The deal is therefore meaningful for skincare but small beside the group, where most of the growth comes from injectables such as Restylane and Nemluvio, a prescription skin treatment whose first-half sales were $433m against $131m.

## Why it matters

Galderma earns money in three ways: injectable treatments for cosmetic procedures, skincare brands, and prescription medicines for skin disease. Physician-dispensed skincare is sold on a doctor's recommendation, so the clinic that already buys a company's injectables is a natural place to sell it cream and serum too. In the first half, US sales were $1,374m, up 32.3% at constant currency, so the United States is the group's largest market. ZO is American-made and strong in the doctor and medical-spa channel, which fits that focus.

For Blackstone, the private equity owner since 2020, the sale ends a roughly six-year holding; the firm says ZO more than doubled its revenue under its ownership, and Reuters reported it had been exploring a sale since at least September. For rivals in medical skincare, a larger Galderma means a bigger shelf in the clinics they also sell to. The main risk the company itself names is financial: margins dip in 2027 before ZO's growth is expected to contribute.

## What to watch next

The dated and factual items are few. Galderma expects completion in the fourth quarter of 2026 or early 2027, once regulatory approvals arrive; it has not named the approvals. It has said it will give mid-term targets beyond 2027 in the first quarter of 2027, after talks with the US Food and Drug Administration about resubmitting its application for relabotulinumtoxinA, an injectable wrinkle treatment, which received a Complete Response Letter, an FDA request for more work, on 1 July 2026. The announcement gives no date for full-year 2026 results, so we give none. Compare later reports against the 2027 margin warning and the stated full-year 2026 targets: net sales growth of 19% to 21% at constant currency and a Core EBITDA margin near 26%.

- Enterprise value: the value of a business including its debt, not just its shares.
- Core EBITDA: Galderma's own adjusted measure of operating profit before depreciation and amortisation.
- Constant currency: growth calculated as if exchange rates had not changed.

> **Why it matters** Galderma is paying about 4.5 times annual sales to add a doctor-recommended skincare brand to its US business. The company itself says the deal will slightly reduce its profit margin in 2027 before improving from 2028.

> **What we verified** From Galderma's press release of 14 Oct 2026 (USD, cash deal): enterprise value $1.5bn; ZO net sales about $330m for the 12 months to June 2026; 40+ products, 16,500+ accounts, 40+ countries; closing Q4 2026 or early 2027; Core EBITDA margin slightly dilutive in 2027, in line from 2028; Core EPS neutral in year one. Price, sales, sellers and timing were also confirmed by Personal Care Insights (15 Oct 2026), AWP Alliance News (14 Oct 2026) and Reuters via Capital.com (13 Oct 2026). Galderma's figures are from its H1 2026 results release (23 Jul 2026, IFRS-based Core measures): sales $3,134m vs $2,448m; Core EBITDA $802m vs $555m; Core EPS $2.34 vs $1.39; net debt $1,786m; US sales $1,374m; Dermatological Skincare $848m vs $719m. The 4.5x multiple, the percentage changes, the pro forma net debt of about $3.3bn and the one-fifth comparison are our calculations. AWP's brief says it was produced with generative AI, so we relied on the company release for each figure.

### Sources
- [Galderma signs agreement to acquire ZO Skin Health (Galderma press release, 14 Oct 2026)](https://www.galderma.com/news/galderma-signs-agreement-acquire-zo-skin-health)
- [Galderma H1 2026 performance (Galderma results release, 23 Jul 2026)](https://www.galderma.com/news/galderma-H12026-performance)
- [Galderma buys ZO Skin Health for US$1.5B to expand dermatological skin care (Personal Care Insights)](https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html)
- [Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say (Reuters via Capital.com)](https://capital.com/en-int/news/galderma-agrees-to-buy-zo-skin-health-for-around-1-5)